title: Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children.
abstract: The distinction between RAEB, RAEB-T and AML M6a is difficult when erythroblasts in the bone marrow (BM) exceed 50%. We analyzed 19 children (2 RAEB, 13 RAEB-T and 4 AML M6a) enrolled in a prospective pathological central review in Japan and divided them into two groups according to the myeloblasts percentage among non-erythroid cells in BM: group A (n = 8), 5-19% myeloblasts; group B (n = 11), 20% or more myeloblasts. Their characteristics were very similar except for the number of myeloblasts. The median WBC was in the range of 1.0-5.0 x 10(9) L(-1), the median Hb was around 7.5 g/dL, the median MCV was greater than 90 fL and both group had Auer rods at 60-65%. Severe multilineage dysplasia was observed in most of the patients in two groups. Six with group A and seven with group B treated with AML type chemotherapy achieved complete remission. Five with group A and seven with group B undergoing SCT are alive at a median of 3 years after diagnosis. Erythroblast-rich RAEB and AML M6a in children have similar characteristics and may belong to a single disease entity.
authors.affiliation: Department of Pediatrics, University of Occupational and Environmental Health, Kitakyusyu, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Honda
authors.affiliation: Department of Pediatrics, St Luke's International Hospital, 9-1, Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. manabe-luke@umin.ac.jp.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Manabe
authors.affiliation: Department of Pediatrics, Ibaraki Children's Hospital, Mito, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tsuchida
authors.affiliation: Laboratory Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Zaike
authors.affiliation: Department of Surgical Pathology, Showa University Fujigaoka Hospital, Yokohama, Japan.
authors.forename: Atsuko
authors.initials: A
authors.lastname: Masunaga
authors.affiliation: Department of Hematology/Oncology, Osaka Medical Center, Research Institute for Maternal and Child Health, Izumi, Japan.
authors.forename: Masami
authors.initials: M
authors.lastname: Inoue
authors.affiliation: Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan.
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kobayashi
authors.affiliation: Department of Pediatrics, Hyogo College of Medicine, Nishinomiya, Japan.
authors.forename: Yoshitoshi
authors.initials: Y
authors.lastname: Ohtsuka
authors.affiliation: Department of Hematology/Oncology, Saitama Children's Medical Center, Iwatsuki, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Kikuchi
authors.affiliation: Department of Pediatrics, Kyoto University, Kyoto, Japan.
authors.forename: Tatsutoshi
authors.initials: T
authors.lastname: Nakahata
mesh_terms: D000293:Adolescent; D000754:Anemia, Refractory, with Excess of Blasts / Q000097:blood / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D004900:Erythroblasts / Q000378:metabolism / Q000473:pathology*; D005260:Female; D042381:Granulocyte Precursor Cells / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007223:Infant; D007564:Japan; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D007958:Leukocyte Count; D008297:Male; D011446:Prospective Studies; D012074:Remission Induction; D033581:Stem Cell Transplantation; D013997:Time Factors; D014184:Transplantation, Homologous